News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
105,239 Results
Type
Article (6573)
Company Profile (13)
Press Release (98653)
Section
Business (41579)
Career Advice (382)
Deals (7392)
Drug Delivery (56)
Drug Development (9998)
Employer Resources (33)
FDA (1790)
Job Trends (1961)
News (60230)
Policy (4401)
Tag
Academia (277)
Alliances (6037)
Alzheimer's disease (165)
Approvals (1776)
Artificial intelligence (41)
Bankruptcy (70)
Best Places to Work (1559)
Breast cancer (40)
Cancer (250)
Cardiovascular disease (32)
Career advice (326)
Cell therapy (70)
Clinical research (7931)
Collaboration (121)
COVID-19 (349)
C-suite (63)
Data (219)
Diabetes (106)
Diagnostics (874)
Drug pricing (53)
Earnings (17395)
Employer resources (31)
Events (11613)
Executive appointments (255)
FDA (1924)
Funding (138)
Gene therapy (45)
GLP-1 (450)
Government (657)
Healthcare (3220)
Infectious disease (369)
Inflammatory bowel disease (29)
Interviews (43)
IPO (3169)
Job creations (438)
Job search strategy (295)
Layoffs (73)
Legal (1117)
Lung cancer (31)
Manufacturing (70)
Medical device (2395)
Medtech (2396)
Mergers & acquisitions (4335)
Metabolic disorders (323)
Neuroscience (232)
NextGen: Class of 2025 (1020)
Non-profit (453)
Northern California (382)
Obesity (210)
Opinion (57)
Patents (29)
People (16899)
Phase I (2496)
Phase II (3652)
Phase III (2805)
Pipeline (174)
Podcasts (34)
Policy (40)
Postmarket research (211)
Preclinical (900)
Radiopharmaceuticals (67)
Rare diseases (63)
Real estate (612)
Regulatory (2947)
Research institute (316)
Resumes & cover letters (51)
Series A (37)
Southern California (278)
Startups (614)
The Weekly (31)
United States (3104)
Vaccines (97)
Weight loss (206)
Date
Last 7 days (102)
Last 30 days (466)
Last 365 days (6640)
2025 (865)
2024 (6798)
2023 (7098)
2022 (9815)
2021 (9961)
2020 (8991)
2019 (7041)
2018 (5538)
2017 (5368)
2016 (4939)
2015 (5627)
2014 (4220)
2013 (3231)
2012 (3486)
2011 (3655)
2010 (3274)
Location
Africa (122)
Arizona (29)
Asia (6998)
Australia (1126)
California (798)
Canada (394)
China (74)
Colorado (68)
Connecticut (47)
Europe (15959)
Florida (122)
Georgia (32)
Illinois (61)
Indiana (73)
Maryland (167)
Massachusetts (500)
Minnesota (40)
New Jersey (380)
New York (188)
North Carolina (162)
Northern California (382)
Ohio (37)
Pennsylvania (161)
South America (187)
Southern California (278)
Texas (126)
Washington State (44)
105,239 Results for "novo holdings".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Novo Holdings Gets FTC’s Go-Ahead for Contentious $16.5B Catalent Acquisition
Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.
December 16, 2024
·
2 min read
·
Tristan Manalac
Rare diseases
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to compete in the hemophilia A space with Roche’s
blockbuster
Hemlibra.
February 7, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
December 19, 2024
·
1 min read
Obesity
Novo Rebounds as Next-Gen Obesity Drug Elicits up to 22% Weight Loss
The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% weight reduction.
January 24, 2025
·
2 min read
·
Tristan Manalac
Earnings
Catalent Misses Fiscal Q1 Revenue Expectations as Pressure Mounts on Novo Holdings’ $16.5B Buyout
The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, 2024. The miss comes amid growing opposition to Novo Holdings’ proposed $16.5 billion acquisition of Catalent.
November 6, 2024
·
3 min read
·
Tristan Manalac
Press Releases
Novo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
December 16, 2024
·
2 min read
Earnings
Despite Doubled Wegovy Sales, Novo Executives Confront Analysts’ Insatiable Appetite
Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.
February 5, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
Novo Holdings Completes Acquisition of Catalent
December 18, 2024
·
4 min read
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
·
2 min read
·
Annalee Armstrong
Press Releases
The European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
December 9, 2024
·
1 min read
1 of 10,524
Next
